NIH Grants Exclusive License for Autoimmune CAR Therapy
Published Date: 2/13/2026
Notice
Summary
The National Cancer Institute plans to give Kyverna Therapeutics an exclusive license to use a special CAR therapy that helps treat or prevent autoimmune diseases caused by B cells. This means Kyverna will be the only company allowed to develop and sell this innovative treatment. If you want to comment or apply for a license, you need to act by March 2, 2026.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Exclusive License to Kyverna for Anti‑CD19 CARs
The National Cancer Institute is contemplating granting Kyverna Therapeutics an exclusive patent license (which may be worldwide) for developing, producing, and commercializing an anti‑CD19 CAR immunotherapy that uses either a non‑viral synthetic nanoparticle system or a viral system (excluding lentiviral) that encapsulates mRNA or DNA encoding a CAR with the Hu19 CDR sequences, for the treatment or prevention of B cell mediated autoimmune diseases.
Deadline to Comment or Apply for License
If you want to comment on or apply for this exclusive license, written comments and/or license applications must be received by the NCI Technology Transfer Center on or before March 2, 2026. License applications filed in response to this notice will be treated as objections to the grant and are presumed to contain business confidential information.
Field of Use Carve-Outs and Royalty Requirement
The contemplated exclusive license would exclude anti‑CD19 CAR approaches that use CRISPR/Cas9‑edited allogeneic T lymphocytes and autologous T lymphocytes engineered by lentivirus, and it does not include CAR constructs that exclusively use the FMC63 antigen binding domain. The prospective exclusive license will be royalty bearing.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11892 — Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute)
The National Cancer Institute wants your thoughts on a new way to track and locate cancer research samples through their Specimen Resource Locator. This affects researchers and labs who use these samples, aiming to make finding and sharing easier without adding extra costs or delays. You’ve got 60 days to share your feedback and help shape this helpful tool!
2026-11390 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-11367 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting science projects. If you’re involved in cell biology, heart disease, mental health, or cancer research, these reviews could impact your funding timeline and opportunities.
2026-11357 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on July 16, 2026, with some parts open to the public and others closed to protect private info and trade secrets. This meeting affects researchers and grant applicants, as grant reviews will happen behind closed doors. Anyone can watch the open sessions online and send comments up to 15 days before the meeting—no registration needed!
2026-11018 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late June and early July 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10813 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Previous / Next Documents
Previous: 2026-02906 — Government Owned Inventions Available for License: Gait Assistance Systems and Methods of Control Thereof
The NIH is offering a license for a smart, robot-powered system that helps people with movement problems walk better by adapting to their unique way of moving. This invention uses machine learning to personalize support in real-time, making walking easier and more natural for kids and adults with conditions like cerebral palsy. Companies interested in bringing this tech to market should act soon to help improve lives and tap into a promising new market.
Next: 2026-02908 — Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to make large amounts of marijuana and related substances for clinical trials and customers. People who already make or use these drugs can comment or ask for a hearing by April 14, 2026. This move could speed up research and distribution, but no other drug activities are allowed under this registration.